Group revenue for the quarter fell 6.1% to $29 million from $30.9 million the preceding year, due primarily to a decline of 14.1% in the specialty pharma principals segment in 2Q19 on the back of higher demand in 2Q18, ahead of products licensing renewal in Vietnam.
SINGAPORE (Aug 13): Hyphens Pharma International reported 2Q19 earnings of $1.6 million, up 1.4% from $1.61 million for the same quarter last year.
Earnings per share for 2Q19 fell to 0.54 cent from 0.63 cent in 2Q18.
